Bernal-Morales, Carolina http://orcid.org/0000-0001-5469-3963
Velazquez-Villoria, Daniel http://orcid.org/0000-0002-8677-6859
Cubero-Parra, Juan Manuel
Keane, Pearse A. http://orcid.org/0000-0002-9239-745X
Sim, Dawn A. http://orcid.org/0000-0002-6363-7805
Adán, Alfredo
Tufail, Adnan
Zarranz-Ventura, Javier http://orcid.org/0000-0003-2338-8143
Article History
Received: 21 October 2020
Revised: 7 February 2021
Accepted: 18 February 2021
First Online: 8 March 2021
Compliance with ethical standards
:
: The authors declare no competing interests.
: CB-M, none; DV-V, none; JMC-P has been in advisory boards, has given lectures and has received travel grants from Alcon, Allergan, Bausch & Lomb, Bayer, DORC and Novartis and has been a lecturer for Novartis and Bausch & Lomb; PAK acts as a consultant for Novartis, Roche, Apellis, and DeepMind, he has received speaker fees from Allergan, Bayer, Topcon, and Heidelberg Engineering and has stocks in Big Picture Eye Health.; DAS no disclosures; AA has been in advisory boards for Abbvie and Novartis; AT has been in advisory boards and has given lectures for Allergan, Alimera Science, Bayer, Novartis and Roche, and has received grants from Medisoft Ltd, Notal Vision and Novartis; JZ-V has been in advisory boards, is a consultant, lecturer and has received travel grants from Alcon, Alimera Science, Allergan, Bausch & Lomb, Bayer, Brill Pharma, DORC, Novartis and Roche, is a grant holder from Allergan and Novartis, and has been a lecturer for Topcon and Zeiss